ipafricept

Home
Ligands
ipafricept

GtoPdb Ligand ID: 10325

Synonyms: FZD8-Fc | OMP-54F28 | OMP54F28

Compound class: Peptide or derivative

Comment: Ipafricept (OMP-54F28) is a fusion protein that fuses the FZD₈ cysteine-rich domain to human IGHG1 Fc fragment [1]. It acts as a soluble decoy receptor for WNT ligands, and exhibits antitumour efficacy in vivo. Produced by OncoMed Pharmaceuticals.

Summary
Biological activity
Clinical data
References

References
1. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. (2007) The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res, 67 (11): 5371-9. [PMID:17545618]
2. Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S et al.. (2017) A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res, 23 (24): 7490-7497. [PMID:28954784]

References

1. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, Rubinfeld B. (2007)
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.
Cancer Res, 67 (11): 5371-9. [PMID:17545618]

2. Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S et al.. (2017)
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Clin Cancer Res, 23 (24): 7490-7497. [PMID:28954784]